Predictors of symptoms are different from predictors of severe exacerbations from asthma in children
- PMID: 21292760
- PMCID: PMC3130529
- DOI: 10.1378/chest.10-2794
Predictors of symptoms are different from predictors of severe exacerbations from asthma in children
Abstract
Background: Asthma therapy is typically prescribed and titrated based on patient or parent self-report of symptoms. No longitudinal studies have assessed the relationship between symptoms and severe asthma exacerbations in children. The goal of our study was (1) to assess the association of asthma symptoms with severe asthma exacerbations and (2) to compare predictors of persistent asthma symptoms and predictors of severe asthma exacerbations.
Methods: The Childhood Asthma Management Program was a multicenter clinical trial of 1,041 children randomized to receive budesonide, nedocromil, or placebo (as-needed β-agonist). We conducted a post hoc analysis of diary cards that were completed by subjects on a daily basis to categorize subjects as having persistent vs intermittent symptoms. We defined a severe asthma exacerbation as an episode requiring ≥ 3 days use of oral corticosteroids, hospitalization, or ED visit due to asthma based on self-report at study visits every 4 months.
Results: While accounting for longitudinal measures, having persistent symptoms from asthma was significantly associated with having severe asthma exacerbations. Predictors of having persistent symptoms compared with intermittent symptoms included not being treated with inhaled corticosteroids, lower FEV(1)/FVC ratio, and a lower natural logarithm of provocative concentration of methacholine producing a 20% decline in FEV(1) (lnPC(20)). Predictors of having one or more severe asthma exacerbations included younger age, history of hospitalization or ED visit in the prior year, ≥ 3 days use of oral corticosteroids in the prior 3 months, lower FEV(1)/FVC ratio, lower lnPC(20), and higher logarithm to the base 10 eosinophil count; treatment with inhaled corticosteroids was predictive of having no severe asthma exacerbations.
Conclusions: Patients with persistent symptoms from asthma were more likely to experience severe asthma exacerbations. Nevertheless, demographic and laboratory predictors of having persistent symptoms are different from predictors of severe asthma exacerbations. Although symptoms and exacerbations are closely related, their predictors are different. The current focus of the National Asthma Education and Prevention Program guidelines on the two separate domains of asthma control, impairment and risk, are supported by our analysis.
Similar articles
-
[Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].Zhonghua Jie He He Hu Xi Za Zhi. 2024 Feb 12;47(2):101-119. doi: 10.3760/cma.j.cn112147-20231019-00247. Zhonghua Jie He He Hu Xi Za Zhi. 2024. PMID: 38309959 Chinese.
-
Long-term effects of budesonide or nedocromil in children with asthma.N Engl J Med. 2000 Oct 12;343(15):1054-63. doi: 10.1056/NEJM200010123431501. N Engl J Med. 2000. PMID: 11027739 Clinical Trial.
-
Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial.Lancet. 2003 Mar 29;361(9363):1071-6. doi: 10.1016/S0140-6736(03)12891-7. Lancet. 2003. PMID: 12672309 Clinical Trial.
-
Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma.Cochrane Database Syst Rev. 2021 May 4;5(5):CD013518. doi: 10.1002/14651858.CD013518.pub2. Cochrane Database Syst Rev. 2021. PMID: 33945639 Free PMC article.
-
Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews.Cochrane Database Syst Rev. 2020 Aug 5;8(8):CD012977. doi: 10.1002/14651858.CD012977.pub2. Cochrane Database Syst Rev. 2020. PMID: 32767571 Free PMC article.
Cited by
-
Past asthma exacerbation in children predicting future exacerbation: a systematic review.ERJ Open Res. 2022 Nov 14;8(4):00174-2022. doi: 10.1183/23120541.00174-2022. eCollection 2022 Oct. ERJ Open Res. 2022. PMID: 36382233 Free PMC article.
-
Exploring the Utility of Noninvasive Type 2 Inflammatory Markers for Prediction of Severe Asthma Exacerbations in Children and Adolescents.J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2624-2633.e2. doi: 10.1016/j.jaip.2019.04.043. Epub 2019 May 14. J Allergy Clin Immunol Pract. 2019. PMID: 31100552 Free PMC article.
-
ITGB5 and AGFG1 variants are associated with severity of airway responsiveness.BMC Med Genet. 2013 Aug 28;14:86. doi: 10.1186/1471-2350-14-86. BMC Med Genet. 2013. PMID: 23984888 Free PMC article.
-
Omalizumab Is Associated with Reduced Acute Severity of Rhinovirus-triggered Asthma Exacerbation.Am J Respir Crit Care Med. 2016 Dec 15;194(12):1552-1555. doi: 10.1164/rccm.201606-1145LE. Am J Respir Crit Care Med. 2016. PMID: 27976938 Free PMC article. No abstract available.
-
Pediatric asthma: natural history, assessment, and treatment.Mt Sinai J Med. 2011 Sep-Oct;78(5):645-60. doi: 10.1002/msj.20285. Mt Sinai J Med. 2011. PMID: 21913196 Free PMC article. Review.
References
-
- Moorman JE, Rudd RA, Johnson CA, et al. Centers for Disease Control and Prevention (CDC) National surveillance for asthma—United States, 1980-2004. MMWR Surveill Summ. 2007;56(8):1–54. - PubMed
-
- National Asthma Education and Prevention Program Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol. 2007;120(suppl 5):S94–S138. - PubMed
-
- Juniper EF, Svensson K, Mörk AC, Ståhl E. Measuring health-related quality of life in adults during an acute asthma exacerbation. Chest. 2004;125(1):93–97. - PubMed
-
- Peters D, Chen C, Markson LE, Allen-Ramey FC, Vollmer WM. Using an asthma control questionnaire and administrative data to predict health-care utilization. Chest. 2006;129(4):918–924. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- N01-HR-16046/HR/NHLBI NIH HHS/United States
- N01-HR-16048/HR/NHLBI NIH HHS/United States
- N01 HR016044/HL/NHLBI NIH HHS/United States
- U01HL075420/HL/NHLBI NIH HHS/United States
- N01-HR-16045/HR/NHLBI NIH HHS/United States
- N01-HR-16052/HR/NHLBI NIH HHS/United States
- K08 HL088046/HL/NHLBI NIH HHS/United States
- U01 HL075416/HL/NHLBI NIH HHS/United States
- M01 RR000051/RR/NCRR NIH HHS/United States
- U01 HL075408/HL/NHLBI NIH HHS/United States
- U01 HL075232/HL/NHLBI NIH HHS/United States
- U01 HL075415/HL/NHLBI NIH HHS/United States
- U01 HL075409/HL/NHLBI NIH HHS/United States
- U01HL075232/HL/NHLBI NIH HHS/United States
- U01HL075409/HL/NHLBI NIH HHS/United States
- N01-HR-16049/HR/NHLBI NIH HHS/United States
- RR00036/RR/NCRR NIH HHS/United States
- U01HL075407/HL/NHLBI NIH HHS/United States
- N01-HR-16051/HR/NHLBI NIH HHS/United States
- U01 HL075407/HL/NHLBI NIH HHS/United States
- M01 RR002719/RR/NCRR NIH HHS/United States
- U01 HL075420/HL/NHLBI NIH HHS/United States
- U01HL075416/HL/NHLBI NIH HHS/United States
- N01-HR-16044/HR/NHLBI NIH HHS/United States
- U01HL075415/HL/NHLBI NIH HHS/United States
- M01 RR000036/RR/NCRR NIH HHS/United States
- M01RR02719-14/RR/NCRR NIH HHS/United States
- U01 HL075417/HL/NHLBI NIH HHS/United States
- U01 HL075419/HL/NHLBI NIH HHS/United States
- U01HL075419/HL/NHLBI NIH HHS/United States
- N01-HR-16050/HR/NHLBI NIH HHS/United States
- U01HL075408/HL/NHLBI NIH HHS/United States
- N01-HR-16047/HR/NHLBI NIH HHS/United States
- U01HL075417/HL/NHLBI NIH HHS/United States
- M01RR00051/RR/NCRR NIH HHS/United States
- M01RR0099718-24/RR/NCRR NIH HHS/United States